Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib

Roberto Latagliata; Massimo Breccia; Fausto Castagnetti; Fabio Stagno; Luigiana Luciano; Antonella Gozzini; Stefano Ulisciani; Francesco Cavazzini; Mario Annunziata; Federica Sora'; Antonella Russo Rossi; Patrizia Pregno; Enrico Montefusco; Elisabetta Abruzzese; Elena Crisà; Pellegrino Musto; Mario Tiribelli; Gianni Binotto; Ubaldo Occhini; Costanzo Feo; Paolo Vigneri; Valeria Santini; Carmen Fava; Giannantonio Rosti; Giuliana Alimena

doi:10.1016/j.leukres.2011.05.015

Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib

Roberto Latagliata
, Massimo Breccia
, Fausto Castagnetti
, Fabio Stagno
, Luigiana Luciano
, Antonella Gozzini
, Stefano Ulisciani
, Francesco Cavazzini
, Mario Annunziata
, Federica Sora'
, Antonella Russo Rossi
, Patrizia Pregno
, Enrico Montefusco
, Elisabetta Abruzzese
, Elena Crisà
, Pellegrino Musto
, Mario Tiribelli
, Gianni Binotto
, Ubaldo Occhini
, Costanzo Feo

Paolo Vigneri, Valeria Santini, Carmen Fava, Giannantonio Rosti, Giuliana Alimena

University of Rome La Sapienza
University of Bologna
Ospedale Ferrarotto
University of Naples Federico II
University of Florence
Ematologia
University of Ferrara
Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli
University of Bari
Azienda Sanitaria Ospedaliera Molinette San Giovanni Battista Di Torino
Sant'Andrea Hospital
ASL Roma 2
University of Turin
IRCCS Centro di riferimento oncologico della Basilicata - Rionero in Vulture (PZ)
University of Udine
University of Padua
IRCCS Policlinico San Donato
DH Ematologico

Risultato della ricerca: Contributo in rivista › Articolo › peer review

30 Citazioni (Scopus)

Abstract

To highlight dasatinib role in the elderly, 125 unselected patients with CP-CML aged >60 years resistant/intolerant to imatinib were retrospectively evaluated. Grade 3-4 haematological and extra-haematological toxicities were reported in 39 (31.2%) and 34 (27.2%) patients; grade 3-4 haematological toxicity was higher in patients with 140 mg starting dose (50.0% vs 19.6%, p=0.001). Grade 3-4 pleuro-pericardial effusions occurred in 10 patients (8.0%). Dose reductions were more common in patients with 140 mg (88.4% vs 26.7%, p<0.001). Of 122 evaluable patients, 72 (59.1%) had cytogenetic response [12 (9.8%) partial, 60 (49.3%) complete]. Overall, 38/60 patients in complete CyR also achieved a molecular response. Cumulative OS at 24 and 48 months were 93.1% (95% CI 88.4-97.8) and 84.2% (95% CI 74.6-93.7). Dasatinib, at the recommended dose of 100mg/day, is effective and safe also in unselected elderly subjects.

Lingua originale	Inglese
pagine (da-a)	1164-1169
Numero di pagine	6
Rivista	Leukemia Research
Volume	35
DOI	https://doi.org/10.1016/j.leukres.2011.05.015
Stato di pubblicazione	Pubblicato - 2011

Keywords

Aged
Antineoplastic Agents
Drug Resistance, Neoplasm
Drug Tolerance
Female
Follow-Up Studies
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Male
Middle Aged
Pyrimidines
Retrospective Studies
Thiazoles
Treatment Outcome

Accesso al documento

10.1016/j.leukres.2011.05.015

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Latagliata, R., Breccia, M., Castagnetti, F., Stagno, F., Luciano, L., Gozzini, A., Ulisciani, S., Cavazzini, F., Annunziata, M., Sora', F., Rossi, A. R., Pregno, P., Montefusco, E., Abruzzese, E., Crisà, E., Musto, P., Tiribelli, M., Binotto, G., Occhini, U., ... Alimena, G. (2011). Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. Leukemia Research, 35, 1164-1169. https://doi.org/10.1016/j.leukres.2011.05.015

@article{c4171a3c14bb415dab84535a6d34b4c8,

title = "Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib",

abstract = "To highlight dasatinib role in the elderly, 125 unselected patients with CP-CML aged >60 years resistant/intolerant to imatinib were retrospectively evaluated. Grade 3-4 haematological and extra-haematological toxicities were reported in 39 (31.2\%) and 34 (27.2\%) patients; grade 3-4 haematological toxicity was higher in patients with 140 mg starting dose (50.0\% vs 19.6\%, p=0.001). Grade 3-4 pleuro-pericardial effusions occurred in 10 patients (8.0\%). Dose reductions were more common in patients with 140 mg (88.4\% vs 26.7\%, p<0.001). Of 122 evaluable patients, 72 (59.1\%) had cytogenetic response [12 (9.8\%) partial, 60 (49.3\%) complete]. Overall, 38/60 patients in complete CyR also achieved a molecular response. Cumulative OS at 24 and 48 months were 93.1\% (95\% CI 88.4-97.8) and 84.2\% (95\% CI 74.6-93.7). Dasatinib, at the recommended dose of 100mg/day, is effective and safe also in unselected elderly subjects.",

keywords = "Aged, Antineoplastic Agents, Drug Resistance, Neoplasm, Drug Tolerance, Female, Follow-Up Studies, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Male, Middle Aged, Pyrimidines, Retrospective Studies, Thiazoles, Treatment Outcome, Aged, Antineoplastic Agents, Drug Resistance, Neoplasm, Drug Tolerance, Female, Follow-Up Studies, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Male, Middle Aged, Pyrimidines, Retrospective Studies, Thiazoles, Treatment Outcome",

author = "Roberto Latagliata and Massimo Breccia and Fausto Castagnetti and Fabio Stagno and Luigiana Luciano and Antonella Gozzini and Stefano Ulisciani and Francesco Cavazzini and Mario Annunziata and Federica Sora' and Rossi, \{Antonella Russo\} and Patrizia Pregno and Enrico Montefusco and Elisabetta Abruzzese and Elena Cris{\`a} and Pellegrino Musto and Mario Tiribelli and Gianni Binotto and Ubaldo Occhini and Costanzo Feo and Paolo Vigneri and Valeria Santini and Carmen Fava and Giannantonio Rosti and Giuliana Alimena",

year = "2011",

doi = "10.1016/j.leukres.2011.05.015",

language = "English",

volume = "35",

pages = "1164--1169",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

}

Latagliata, R, Breccia, M, Castagnetti, F, Stagno, F, Luciano, L, Gozzini, A, Ulisciani, S, Cavazzini, F, Annunziata, M, Sora', F, Rossi, AR, Pregno, P, Montefusco, E, Abruzzese, E, Crisà, E, Musto, P, Tiribelli, M, Binotto, G, Occhini, U, Feo, C, Vigneri, P, Santini, V, Fava, C, Rosti, G & Alimena, G 2011, 'Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib', Leukemia Research, vol. 35, pagg. 1164-1169. https://doi.org/10.1016/j.leukres.2011.05.015

TY - JOUR

T1 - Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib

AU - Latagliata, Roberto

AU - Breccia, Massimo

AU - Castagnetti, Fausto

AU - Stagno, Fabio

AU - Luciano, Luigiana

AU - Gozzini, Antonella

AU - Ulisciani, Stefano

AU - Cavazzini, Francesco

AU - Annunziata, Mario

AU - Sora', Federica

AU - Rossi, Antonella Russo

AU - Pregno, Patrizia

AU - Montefusco, Enrico

AU - Abruzzese, Elisabetta

AU - Crisà, Elena

AU - Musto, Pellegrino

AU - Tiribelli, Mario

AU - Binotto, Gianni

AU - Occhini, Ubaldo

AU - Feo, Costanzo

AU - Vigneri, Paolo

AU - Santini, Valeria

AU - Fava, Carmen

AU - Rosti, Giannantonio

AU - Alimena, Giuliana

PY - 2011

Y1 - 2011

N2 - To highlight dasatinib role in the elderly, 125 unselected patients with CP-CML aged >60 years resistant/intolerant to imatinib were retrospectively evaluated. Grade 3-4 haematological and extra-haematological toxicities were reported in 39 (31.2%) and 34 (27.2%) patients; grade 3-4 haematological toxicity was higher in patients with 140 mg starting dose (50.0% vs 19.6%, p=0.001). Grade 3-4 pleuro-pericardial effusions occurred in 10 patients (8.0%). Dose reductions were more common in patients with 140 mg (88.4% vs 26.7%, p<0.001). Of 122 evaluable patients, 72 (59.1%) had cytogenetic response [12 (9.8%) partial, 60 (49.3%) complete]. Overall, 38/60 patients in complete CyR also achieved a molecular response. Cumulative OS at 24 and 48 months were 93.1% (95% CI 88.4-97.8) and 84.2% (95% CI 74.6-93.7). Dasatinib, at the recommended dose of 100mg/day, is effective and safe also in unselected elderly subjects.

AB - To highlight dasatinib role in the elderly, 125 unselected patients with CP-CML aged >60 years resistant/intolerant to imatinib were retrospectively evaluated. Grade 3-4 haematological and extra-haematological toxicities were reported in 39 (31.2%) and 34 (27.2%) patients; grade 3-4 haematological toxicity was higher in patients with 140 mg starting dose (50.0% vs 19.6%, p=0.001). Grade 3-4 pleuro-pericardial effusions occurred in 10 patients (8.0%). Dose reductions were more common in patients with 140 mg (88.4% vs 26.7%, p<0.001). Of 122 evaluable patients, 72 (59.1%) had cytogenetic response [12 (9.8%) partial, 60 (49.3%) complete]. Overall, 38/60 patients in complete CyR also achieved a molecular response. Cumulative OS at 24 and 48 months were 93.1% (95% CI 88.4-97.8) and 84.2% (95% CI 74.6-93.7). Dasatinib, at the recommended dose of 100mg/day, is effective and safe also in unselected elderly subjects.

KW - Aged

KW - Antineoplastic Agents

KW - Drug Resistance, Neoplasm

KW - Drug Tolerance

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Leukemia, Myelogenous, Chronic, BCR-ABL Positive

KW - Male

KW - Middle Aged

KW - Pyrimidines

KW - Retrospective Studies

KW - Thiazoles

KW - Treatment Outcome

KW - Aged

KW - Antineoplastic Agents

KW - Drug Resistance, Neoplasm

KW - Drug Tolerance

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Leukemia, Myelogenous, Chronic, BCR-ABL Positive

KW - Male

KW - Middle Aged

KW - Pyrimidines

KW - Retrospective Studies

KW - Thiazoles

KW - Treatment Outcome

UR - http://hdl.handle.net/10807/15154

U2 - 10.1016/j.leukres.2011.05.015

DO - 10.1016/j.leukres.2011.05.015

M3 - Article

SN - 0145-2126

VL - 35

SP - 1164

EP - 1169

JO - Leukemia Research

JF - Leukemia Research

ER -

Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo